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Purpose: The development and validation of biochemical mark-
ers for osteoarthritis may accelerate the pace of therapeutic
development. We used data from a longitudinal observation
study to determine if markers of cartilage turnover could serve
as predictors of cartilage loss on MRI.
Methods: We conducted a cross sectional analysis of data from
the Boston Osteoarthritis of the Knee Study (BOKS); a com-
pleted natural history study of knee osteoarthritis. All subjects in
the study met ACR criteria for knee OA. Knee MR images were
scored for cartilage loss using the WORMS semi-quantitative
grading scheme. Within the BOKS population 80 subjects with
cartilage loss and 80 subjects without cartilage loss were se-
lected for the purposes of this nested case control study. We
assessed the baseline levels of cartilage degradation and syn-
thesis products (Col2:3/4Cshort (C1, 2C) with Col2:3/4Clongmono
(C2C); Col II C- telopeptide (Col2CTx); C-propeptide of type II
collagen; Aggrecan 846 Epitope; COMP). We performed a logis-
tic regression to examine the relation of levels of each biomarker
to the risk of cartilage loss in any plate. Cartilage loss was
defined as an increase in cartilage score in any of the plates
previously mentioned. Considering that the risk profiles of carti-
lage loss and magnitude of effect of a particular biomarker on
cartilage loss may be different between men and women, we first
conducted separate analyses for each sex. As the magnitude of
effect of biomarkers was similar for men and women, we then
performed the analysis adjusting for gender, age and BMI.
Results: 160 persons with symptomatic knee OA were as-
sessed. At baseline the mean (SD) age was 67 (9) years
and 54% were male. 76% of the subjects had radiographic
tibiofemoral osteoarthritis (K&L ≥ 2) whilst the remainder had
patellofemoral OA. The results of the logistic regression for uni-
variate biomarker predictors with the outcome cartilage loss in
any plate are displayed in the table. With the exception of COMP
none of the other biomarkers were statistically significant predic-
tors of cartilage loss. For COMP a 1 standard deviation increase
in COMP increased the odds of subsequent cartilage loss 1.49
times (95%CI 1.04-2.14). The c statistic for the univariate as-
sociation was 0.60. After adjusting the analysis for COMP for
Standardized cartilage biomarkers and their respective prediction of subsequent
MRI cartilage loss
Unadjusted AUC p value Adjusted (Age,s ex, BMI)
OR (95% CI) OR (95% CI)
COMP 1.49 (1.04-2.14) 0.60 0.03 1.51 (1.04-2.18)
846 Epitope 0.95 (0.66-1.35) 0.53 0.76 0.98 (0.68-1.41)
CPII 1.08 (0.78-1.52) 0.53 0.64 1.07 (0.76-1.51)
C1,2C 0.85 (0.61-1.19) 0.55 0.35 0.87 (0.62-1.23)
Col2CTX/Cr ratio 1.21 (0.78-1.89) 0.49 0.39 1.18 (0.76-1.83)
C2C 0.69 (0.46-1.04) 0.58 0.08 0.70 (0.46-1.05)
age, sex and BMI the odds for cartilage loss was 1.51 (95%
CI1.04-2.18).
None of the ratios of uncoupling of biomarker predictors facili-
tated prediction of cartilage loss.
Conclusions: Increased COMP levels predict subsequent car-
tilage loss on MRI. The other biochemical markers of cartilage
synthesis and degradation do not facilitate prediction of cartilage
loss. With the exception of COMP if changes in cartilage turnover
in persons with symptomatic knee OA are associated with carti-
lage loss, they do not appear to affect systemic biomarker levels.
Based on these data we would not advocate their use as markers
to predict progression in persons with symptomatic knee OA.
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Purpose: Inflammation may contribute to progression of os-
teoarthritis (OA). Therefore, we investigated whether variations
in the innate ex vivo production of interleukin (IL)-1β, tumor
necrosis factor (TNF)-α, IL-1 receptor antagonist (Ra) and IL-10
in whole blood assays upon lipopolysaccharide (LPS) stimulation
is associated with the radiological progression of knee OA.
Methods: 89 participants of the GARP (Genetics, ARthrosis and
Progression) prospective cohort study with symptomatic OA of
the knee were included. Standardised posteroanterior weight-
bearing radiographs of both knees were obtained at baseline
and after 24 months using the non-fluoroscopic fixed-flexion pro-
tocol. Medial and lateral tibiofemoral joint space narrowing (JSN)
of both knees were graded (0-3) with the OARSI atlas. Radio-
graphs were read in pairs without knowledge of the chronology.
Radiological progression was defined as an increase of at least 1
score in JSN total scores. Whole-blood samples were stimulated
with LPS (10 ng/ml). Cytokines in the supernatants were mea-
sured by enzyme-linked immunosorbent assay. The relative risk
(RR) of progression of OA in relation to quartiles of innate ex vivo
production of IL-1β, TNF-α, IL-1 Ra and IL-10 were calculated
and are reported with 95% confidence intervals (CI95) computed
using robust standard errors to take into account the intrafamily
effect.
Results: Progression of JSN was present in 29 (33.7%) of the 86
followed patients after two years. The mean production of IL-1β
and IL-1Ra was not different in patients with JSN progression
compared to patients without. In patients with JSN progression,
the mean production of TNF-α was 1.11 pg/ml higher (CI95
1.03-1.22) and of IL-10 was 1.10 pg/ml higher (CI95 1.01-1.20)
compared to patients without JSN progression. Subjects in the
highest quartile of TNF-α production had a 6-fold increased risk
of JSN progression (age, sex and body mass index adjusted
RR 6.1, CI95 1.4-9.8) and subjects in the highest quartile of
IL-10 production had a 4-fold increased risk of JSN progression
(age, sex and body mass index adjusted RR 4.3, CI95 1.7-6.2),
both in comparison with those subjects in the lowest quartile. No
significant associations were found between variations in IL-1β
and IL-1Ra production and JSN progression.
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